Last reviewed · How we verify
Salmonella typhi vaccination
At a glance
| Generic name | Salmonella typhi vaccination |
|---|---|
| Sponsor | NHS Greater Glasgow and Clyde |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine (PHASE1)
- ZyVac-TCV Bangladesh Study (PHASE3)
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (PHASE4)
- Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (PHASE2)
- Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease (PHASE1)
- Cellular Immune Responses in Typhoid Fever Patients and Vaccinees (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmonella typhi vaccination CI brief — competitive landscape report
- Salmonella typhi vaccination updates RSS · CI watch RSS
- NHS Greater Glasgow and Clyde portfolio CI